EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Study of fluoroquinolones resistance in rifampicin‐resistant tuberculosis patients in Beijing: Characteristics, trends, and treatment outcomes

Wang Nenhan, Tian Lili, Zhao Yanfeng, Chen Shuangshuang, Tao LiYing, Li Qiao, Li Chuanyou, Dai Xiaowei iD

Animal Models and Experimental Medicine · 2025

DOI: 10.1002/ame2.12505 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Animal Models and Experimental Medicine, 2025. Verfasst von Wang Nenhan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Center for Disease Prevention and Control, Beijing, People's Republic of China. Hauptthemen laut MEDLINE: Fluoroquinolones, Rifampin, Tuberculosis, Multidrug-Resistant, Antitubercular Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Research and Cultivation Spectial Project of Beijing Center for Disease Prevention and Control.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

China is a high‐burden country for multidrug‐resistant tuberculosis/rifampin‐resistant tuberculosis (MDR/RR‐TB). Fluoroquinolones (FQs) are key drugs for the treatment of patients with MDR/RR‐TB. However, research on the resistance of FQs in Beijing is limited.

Methods

We collected clinical isolates from all patients with pulmonary TB in Beijing from January 2016 to December 2021, conducted drug‐sensitivity tests and sequencing for levofloxacin (LFX) and moxifloxacin (MFX), and collected the treatment plans and outcomes of the patients.

Results

A total of 8512 clinical isolates were collected from patients with pulmonary TB, and 261 RR‐TB strains were screened. The proportions of drug‐sensitive and drug‐resistant strains significantly differed by age group and treatment history. The rates of LFX and MFX resistance were 27.6% (72/261) and 36.4% (95/261), respectively. The detection rates of MDR‐TB and pre‐extensively drug‐resistant TB (pre‐XDR‐TB) were 73.2% (191/261) and 36.4% (95/261), respectively, and the trends were significant ( χ 2 trend = 9.995, p = 0.002; χ 2 trend = 12.744, p = 0.026). Among the 261 RR‐TB strains, 14.9% (24/261) were sensitive to LFX but resistant to MFX. Among the four patients with LFX‐resistant TB who received LFX treatment failed in three patients(Fisher's exact test, p = 0.009). The common mutation sites were 94 and 90 in gyrA. A novel mutation Ala90Ser was discovered.

Conclusions

FQs resistance trends in RR‐TB patients in Beijing are striking. Strains showed incomplete cross‐resistance to LFX and MFX. Testing for FQs resistance and developing a reasonable treatment plan are recommended. Attention should be given to the changing trends in MDR‐TB and pre‐XDR‐TB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluoroquinolonesRifampinTuberculosis, Multidrug-ResistantAntitubercular AgentsHumansMaleFemaleAdultMiddle AgedBeijingMycobacterium tuberculosisMicrobial Sensitivity TestsMoxifloxacinTreatment OutcomeYoung AdultLevofloxacinAgedAdolescentDrug Resistance, BacterialChinaTuberculosis, Pulmonary

Stichwörter der Autor:innen

mycobacterium tuberculosisdrug resistancelevofloxacinmoxifloxacinpre‐XDR‐TB

Substanzen

FluoroquinolonesRifampinAntitubercular AgentsMoxifloxacinLevofloxacin

Autor:innen und Institutionen

  • Beijing Center for Disease Prevention and Control, Beijing, People's Republic of China.
  • Institute of Pathogen Biology, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.

ORCID-Profile: Dai Xiaowei

Förderung

  • The Research and Cultivation Spectial Project of Beijing Center for Disease Prevention and Control

Zitieren

APA

Nenhan, W., Lili, T., Yanfeng, Z., Shuangshuang, C., LiYing, T., Qiao, L., Chuanyou, L., & Xiaowei, D. (2025). Study of fluoroquinolones resistance in rifampicin‐resistant tuberculosis patients in Beijing: Characteristics, trends, and treatment outcomes. Animal Models and Experimental Medicine. https://doi.org/10.1002/ame2.12505

Vancouver

Nenhan W, Lili T, Yanfeng Z, Shuangshuang C, LiYing T, Qiao L, et al. Study of fluoroquinolones resistance in rifampicin‐resistant tuberculosis patients in Beijing: Characteristics, trends, and treatment outcomes. Animal Models and Experimental Medicine. 2025. doi:10.1002/ame2.12505

BibTeX
@article{Nenhan2025,
  author = {Nenhan, Wang and Lili, Tian and Yanfeng, Zhao and Shuangshuang, Chen and LiYing, Tao and Qiao, Li and Chuanyou, Li and Xiaowei, Dai},
  title = {Study of fluoroquinolones resistance in rifampicin‐resistant tuberculosis patients in Beijing: Characteristics, trends, and treatment outcomes},
  journal = {Animal Models and Experimental Medicine},
  year = {2025},
  doi = {10.1002/ame2.12505}
}
Kostenlos starten →